HtrA3 is regulated by 15-deoxy-Δ12,14-prostaglandin J2 independently of PPARγ in clear cell renal cell carcinomas

Biochemical and Biophysical Research Communications

Volumn 394, Issue 3, 2010, Pages 453-458

  Théoleyre, Sandrine ^a   Mottier, Stéphanie ^a   Masson, Damien ^a,b   Denis, Marc G ^a,b  

^a UNIVERSITÉ DE RENNES 1   (France)

^b INSERM   (France)

Author keywords

15 Deoxy 12,14 prostaglandin J2; HtrA3; PPAR ; Renal cell carcinoma

Indexed keywords

15 DEOXY DELTA12,14 PROSTAGLANDIN J2; 2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 CHLORO 5 NITROBENZANILIDE; CIGLITAZONE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA ANTAGONIST; ROSIGLITAZONE; SERINE PROTEINASE OMI; TRANSFORMING GROWTH FACTOR BETA;

ARTICLE; CLEAR CELL CARCINOMA; CONTROLLED STUDY; DRUG MECHANISM; GENE CONTROL; GENE EXPRESSION; HTRA3 GENE; HUMAN; HUMAN CELL; KIDNEY CARCINOMA; MIGRATION INHIBITION; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE;

CARCINOMA, RENAL CELL; CELL LINE, TUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KIDNEY NEOPLASMS; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; PPAR GAMMA; PROSTAGLANDIN D2; RNA STABILITY; RNA, MESSENGER; SERINE ENDOPEPTIDASES;

EID: 77950517447     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2009.11.163     Document Type: Article

References (43)

1. Patard J.J., Pouessel D., Bensalah K., and Culine S. Targeted therapy in renal cell carcinoma. World J. Urol. 26 (2008) 135-140
2. Rini B.I. Vascular endothelial growth factor-targeted therapy in metastatic renal cell carcinoma. Cancer 115 (2009) 2306-2312
3. Michalik L., Desvergne B., and Wahli W. Peroxisome-proliferator-activated receptors and cancers: complex stories. Nat. Rev. Cancer 4 (2004) 61-70
4. Koeffler H.P. Peroxisome proliferator-activated receptor gamma and cancers. Clin. Cancer Res. 9 (2003) 1-9
5. Wang T., Xu J., Yu X., Yang R., and Han Z.C. Peroxisome proliferator-activated receptor gamma in malignant diseases. Crit. Rev. Oncol. Hematol. 58 (2006) 1-14
6. Jinyang Y., Atsushi T., Naoya M., Naoki I., and Taiji T. Peroxisome proliferator-activated receptor gamma is frequently underexpressed in renal cell carcinoma. Int. J. Urol. 13 (2006) 265-270
7. Inoue K., Kawahito Y., Tsubouchi Y., Kohno M., Yoshimura R., Yoshikawa T., and Sano H. Expression of peroxisome proliferator-activated receptor gamma in renal cell carcinoma and growth inhibition by its agonists. Biochem. Biophys. Res. Commun. 287 (2001) 727-732
8. Yuan J., Takahashi A., Masumori N., Uchida K., Hisasue S., Kitamura H., Itoh N., and Tsukamoto T. Ligands for peroxisome proliferator-activated receptor gamma have potent antitumor effect against human renal cell carcinoma. Urology 65 (2005) 594-599
9. Yang F.G., Zhang Z.W., Xin D.Q., Shi C.J., Wu J.P., Guo Y.L., and Guan Y.F. Peroxisome proliferator-activated receptor gamma ligands induce cell cycle arrest and apoptosis in human renal carcinoma cell lines. Acta Pharmacol. Sin. 26 (2005) 753-761
10. Spiess C., Beil A., and Ehrmann M. A temperature-dependent switch from chaperone to protease in a widely conserved heat shock protein. Cell 97 (1999) 339-347
11. Nie G.Y., Hampton A., Li Y., Findlay J.K., and Salamonsen L.A. Identification and cloning of two isoforms of human high-temperature requirement factor A3 (HtrA3), characterization of its genomic structure and comparison of its tissue distribution with HtrA1 and HtrA2. Biochem. J. 371 (2003) 39-48
12. Nie G.Y., Li Y., Minoura H., Batten L., Ooi G.T., Findlay J.K., and Salamonsen L.A. A novel serine protease of the mammalian HtrA family is up-regulated in mouse uterus coinciding with placentation. Mol. Hum. Reprod. 9 (2003) 279-290
13. Nie G., Li Y., Hale K., Okada H., Manuelpillai U., Wallace E.M., and Salamonsen L.A. Serine peptidase HTRA3 is closely associated with human placental development and is elevated in pregnancy serum. Biol. Reprod. 74 (2006) 366-374
14. Jiraporn T., Akiho T., Miwa K., Yoshifumi U., Chio O., and Masashi K. Developmentally regulated expression of mouse HtrA3 and its role as an inhibitor of TGF-β signaling. Dev. Growth Differ. 46 (2004) 257-274
15. Bowden M.A., Di Nezza-Cossens L.A., Jobling T., Salamonsen L.A., and Nie G. Serine proteases HTRA1 and HTRA3 are down-regulated with increasing grades of human endometrial cancer. Gynecol. Oncol. 103 (2006) 253-260
16. Narkiewicz J., Lapinska-Szumczyk S., Zurawa-Janicka D., Skorko-Glonek J., Emerich J., and Lipinska B. Expression of human HtrA1, HtrA2, HtrA3 and TGF-beta1 genes in primary endometrial cancer. Oncol. Rep. 21 (2009) 1529-1537
17. Narkiewicz J., Klasa-Mazurkiewicz D., Zurawa-Janicka D., Skorko-Glonek J., Emerich J., and Lipinska B. Changes in mRNA and protein levels of human HtrA1, HtrA2 and HtrA3 in ovarian cancer. Clin. Biochem. 41 (2008) 561-569
18. Rageul J., Mottier S., Jarry A., Shah Y., Theoleyre S., Masson D., Gonzalez F.J., Laboisse C.L., and Denis M.G. KLF4-dependent, PPARγ-induced expression of GPA33 in colon cancer cell lines. Int. J. Cancer 125 (2009) 2802-2809
19. Yoon J.C., Chickering T.W., Rosen E.D., Dussault B., Qin Y., Soukas A., Friedman J.M., Holmes W.E., and Spiegelman B.M. Peroxisome proliferator-activated receptor gamma target gene encoding a novel angiopoietin-related protein associated with adipose differentiation. Mol. Cell. Biol. 20 (2000) 5343-5349
20. Kersten S., Mandard S., Tan N.S., Escher P., Metzger D., Chambon P., Gonzalez F.J., Desvergne B., and Wahli W. Characterization of the fasting-induced adipose factor FIAF, a novel peroxisome proliferator-activated receptor target gene. J. Biol. Chem. 275 (2000) 28488-28493
21. Huang J.T., Welch J.S., Ricote M., Binder C.J., Willson T.M., Kelly C., Witztum J.L., Funk C.D., Conrad D., and Glass C.K. Interleukin-4-dependent production of PPAR-gamma ligands in macrophages by 12/15-lipoxygenase. Nature 400 (1999) 378-382
22. Wilmer W.A., Dixon C., Lu L., Hilbelink T., and Rovin B.H. A cyclopentenone prostaglandin activates mesangial MAP kinase independently of PPARγ. Biochem. Biophys. Res. Commun. 281 (2001) 57-62
23. Patel K.M., Wright K.L., Whittaker P., Chakravarty P., Watson M.L., and Ward S.G. Differential modulation of COX-2 expression in A549 airway epithelial cells by structurally distinct PPAR(γ) agonists: evidence for disparate functional effects which are independent of NF-(κ)B and PPAR(γ). Cell Signal. 17 (2005) 1098-1110
24. Chen Z.Y., and Tseng C.-C. 15-Deoxy-Δ12,14 prostaglandin J2 up-regulates Kruppel-like factor 4 expression independently of peroxisome proliferator-activated receptor γ by activating the mitogen-activated protein kinase/extracellular signal-regulated kinase signal transduction pathway in HT-29 colon cancer cells. Mol. Pharmacol. 68 (2005) 1203-1213
25. Zhang Y.Q., Tang X.Q., Sun L., Dong L., Qin Y., Liu H.Q., Xia H., and Cao J.G. Rosiglitazone enhances fluorouracil-induced apoptosis of HT-29 cells by activating peroxisome proliferator-activated receptor gamma. World J. Gastroenterol. 13 (2007) 1534-1540
26. Girnun G.D., Chen L., Silvaggi J., Drapkin R., Chirieac L.R., Padera R.F., Upadhyay R., Vafai S.B., Weissleder R., Mahmood U., Naseri E., Buckley S., Li D., Force J., McNamara K., Demetri G., Spiegelman B.M., and Wong K.-K. Regression of drug-resistant lung cancer by the combination of rosiglitazone and carboplatin. Clin. Cancer Res. 14 (2008) 6478-6486
27. Yu H.N., Noh E.M., Lee Y.R., Roh S.G., Song E.K., Han M.K., Lee Y.C., Shim I.K., Lee S.J., Jung S.H., Kim J.S., and Youn H.J. Troglitazone enhances tamoxifen-induced growth inhibitory activity of MCF-7 cells. Biochem. Biophys. Res. Commun. 377 (2008) 242-247
28. Lee S.Y., Hur G.Y., Jung K.H., Jung H.C., Lee S.Y., Kim J.H., Shin C., Shim J.J., In K.H., Kang K.H., and Yoo S.H. PPAR-γ agonist increase gefitinib's antitumor activity through PTEN expression. Lung Cancer 51 (2006) 297-301
29. Chien J., Campioni M., Shridhar V., and Baldi A. HtrA serine proteases as potential therapeutic targets in cancer. Curr. Cancer Drug Targets 9 (2009) 451-468
30. Cilenti L., Kyriazis G.A., Soundarapandian M.M., Stratico V., Yerkes A., Park K.M., Sheridan A.M., Alnemri E.S., Bonventre J.V., and Zervos A.S. Omi/HtrA2 protease mediates cisplatin-induced cell death in renal cells. Am. J. Physiol. Renal Physiol. 288 (2005) F371-F379
31. Chien J., Aletti G., Baldi A., Catalano V., Muretto P., Keeney G.L., Kalli K.R., Staub J., Ehrmann M., Cliby W.A., Lee Y.K., Bible K.C., Hartmann L.C., Kaufmann S.H., and Shridhar V. Serine protease HtrA1 modulates chemotherapy-induced cytotoxicity. J. Clin. Invest. 116 (2006) 1994-2004
32. Chien J., Ota T., Aletti G., Shridhar R., Boccellino M., Quagliuolo L., Baldi A., and Shridhar V. Serine protease HtrA1 associates with microtubules and inhibits cell migration. Mol. Cell. Biol. 29 (2009) 4177-4187
33. Chien J., Staub J., Hu S.I., Erickson-Johnson M.R., Couch F.J., Smith D.I., Crowl R.M., Kaufmann S.H., and Shridhar V. A candidate tumor suppressor HtrA1 is downregulated in ovarian cancer. Oncogene 23 (2004) 1636-1644
34. Patard J.J., Rioux-Leclercq N., Masson D., Zerrouki S., Jouan F., Collet N., Dubourg C., Lobel B., Denis M., and Fergelot P. Absence of VHL gene alteration and high VEGF expression are associated with tumour aggressiveness and poor survival of renal-cell carcinoma. Br. J. Cancer 101 (2009) 1417-1424
35. Alvarez-Maqueda M., El Bekay R., Alba G., Monteseirin J., Chacon P., Vega A., Martin-Nieto J., Bedoya F.J., Pintado E., and Sobrino F. 15-Deoxy-Δ12,14-prostaglandin J2 induces heme oxygenase-1 gene expression in a reactive oxygen species-dependent manner in human lymphocytes. J. Biol. Chem. 279 (2004) 21929-21937
36. Kim D.H., Kim J.H., Kim E.H., Na H.K., Cha Y.N., Chung J.H., and Surh Y.J. 15-Deoxy-Δ12,14-prostaglandin J2 upregulates the expression of heme oxygenase-1 and subsequently matrix metalloproteinase-1 in human breast cancer cells: possible roles of iron and ROS. Carcinogenesis 30 (2009) 645-654
37. Lappas M., Permezel M., and Rice G.E. 15-Deoxy-Δ(12,14)-prostaglandin J(2) and troglitazone regulation of the release of phospholipid metabolites, inflammatory cytokines and proteases from human gestational tissues. Placenta 27 (2006) 1060-1072
38. Chiba T., Ueki S., Ito W., Kato H., Takeda M., Kayaba H., Furue M., and Chihara J. 15-Deoxy-Δ(12,14)-prostaglandin J2 induces IL-8 and GM-CSF in a human airway epithelial cell line (NCI-H292). Int. Arch. Allergy Immunol. 149 Suppl. 1 (2009) 77-82
39. Chaffer C.L., Thomas D.M., Thompson E.W., and Williams E.D. PPARγ-independent induction of growth arrest and apoptosis in prostate and bladder carcinoma. BMC Cancer 6 (2006) 53
40. Jozkowicz A., Huk I., Nigisch A., Cisowski J., Weigel G., and Dulak J. Prostaglandin-J(2) upregulates expression of matrix metalloproteinase-1 independently of activation of peroxisome proliferator-activated receptor-γ. Acta Biochim. Pol. 50 (2003) 677-689
41. Mix K.S., Coon C.I., Rosen E.D., Suh N., Sporn M.B., and Brinckerhoff C.E. Peroxisome proliferator-activated receptor-gamma-independent repression of collagenase gene expression by 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid and prostaglandin 15-deoxy-Δ(12,14) J2: a role for Smad signaling. Mol. Pharmacol. 65 (2004) 309-318
42. Kimura H., Li X., Torii K., Okada T., Takahashi N., Fujii H., Ishihara S., and Yoshida H. A natural PPAR-γ agonist, 15-deoxy-Δ12,14-prostaglandin J2, may act as an enhancer of PAI-1 in human proximal renal tubular cells under hypoxic and inflammatory conditions. Nephrol. Dial. Transplant. 23 (2008) 2496-2503
43. Sawai H., Liu J., Reber H.A., Hines O.J., and Eibl G. Activation of peroxisome proliferator-activated receptor-γ decreases pancreatic cancer cell invasion through modulation of the plasminogen activator system. Mol. Cancer Res. 4 (2006) 159-167